Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Monovalent subvirion H5N1 influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | ACTIVE_COMPARATOR | - |
| 8 | ACTIVE_COMPARATOR | - |
| 9 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Monovalent subvirion H5N1 influenza vaccine | BIOLOGICAL | 0.5 mL, IM, 2 injections, Formulation 1 |
| Physiological saline | BIOLOGICAL | 0.5 mL, IM, 2 injections |
Inclusion Criteria : * Healthy adult aged 18 to 40 years on the day of inclusion. * Provides signed informed consent prior to study procedures. * Able to attend all scheduled visits and comply with all trial procedures. * For a woman of child-bearing potential, avoid becoming pregnant (use of an ef...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
The monovalent subvirion H5N1 influenza vaccine is an investigational vaccine developed by Sanofi that targets the H5N1 strain of influenza. It is a split virion, inactivated vaccine designed for intramuscular administration. It is intended to protect against H5N1 influenza virus infection and has been studied in healthy adult volunteers.
Sanofi, which trades under the ticker SNY, is the developer of the monovalent subvirion H5N1 influenza vaccine. Sanofi conducted the clinical development of this vaccine candidate. The company is a global pharmaceutical and vaccine manufacturer.
The monovalent subvirion H5N1 influenza vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 1 trial has been completed, and no active trials are currently listed for this vaccine candidate.
The monovalent subvirion H5N1 influenza vaccine was studied in a completed Phase 1 trial, NCT00664417, titled "Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine." The trial enrolled 375 participants in the United States, was randomized and placebo-controlled, and included healthy volunteers aged 18 years and older.
The monovalent subvirion H5N1 influenza vaccine is being developed for the prevention of influenza caused by the H5N1 virus. It is intended for use in healthy adult volunteers. The vaccine targets Orthomyxoviridae infections, the family of viruses that includes influenza.